STAT3 activation inhibits antitumor immune responses.149 Shaomeng Wang research team designed and synthesizeda series of potential STAT3 degraders the development of a small-moleculePROTAC targeting STAT3.150 Known as SD-36,this PROTAC potently and selectively degraded STAT3 protein lymphomaand leukemia cells, while also mediating complete tumor regressionin mouse tumor models.151 The warhead forSD-36 was the small molecule SI-109, a STAT3 SH2 domain inhibitorreported to bind to STAT3 with high affinity. Here, STAT3 is linked to leukemia.